regulatory
confidence high
sentiment negative
materiality 0.92
FDA issues Complete Response Letter for Summit's ivonescimab BLA in EGFR-mutant NSCLC
Summit Therapeutics Inc.
- FDA said substantial evidence of effectiveness is not established without a statistically significant overall survival benefit; PFS benefit alone failed to support a positive benefit-risk profile.
- HARMONi met its PFS primary endpoint, but the primary OS analysis showed only a positive trend that was not statistically significant.
- Post-hoc longer follow-up showed OS hazard ratio of 0.76 across the full, Asian and western patient populations.
- Safety: 16 patients (7.3%) discontinued ivonescimab for TRAEs vs 11 (5.0%) on placebo; treatment-related deaths 4 (1.8%) vs 5 (2.3%).
- Ivonescimab remains unapproved in the U.S. and Europe (China approval May 2024); Summit cites five positive Phase III studies and ongoing HARMONi-3, -7, -GI3, -GU1 trials.
Featured in Daily 8-K Digest
Selected #2 for 2026-11-16.
Read digest